Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk
As a first-line treatment for advanced EGFRm NSCLC, TAGRISSO significantly improved OS and PFS vs comparator EGFR-TKIs.3,4
18.9 months vs 10.2 months with gefitinib/erlotinib
HR=0.46 (95% CI: 0.37–0.57; P<0.0001)3
Primary endpoint
38.6 months vs 31.8 months with gefitinib/erlotinib
HR=0.799 (95% CI: 0.641–0.997; P=0.0462)4
Secondary endpoint
Adapted from TAGRISSO (osimertinib) 40 mg and 80 mg Summary of Product Characteristics.1,2
CI, confidence interval; HR, hazard ratio; PFS, progression-free survival
Adapted from TAGRISSO (osimertinib) 40 mg and 80 mg Summary of Product Characteristics.1,2
*PFS was the primary endpoint. OS was a prespecified secondary endpoint; statistically significant HR for OS was demonstrated (HR=0.799; 95.05% CI: 0.641–0.997; P=0.0462).1,2,4
CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; OS, overall survival
Patients were approximately half as likely to develop new CNS metastases with TAGRISSO compared to gefitinib/erlotinib (RRR=52%, ARR at 18 months=18%; HR=0.48; 95% CI: 0.26–0.86, P=0.014).*5
Adapted from Reungwetwattana T et al. 2018.5
*CNS PFS was measured per blinded independent central review. Patients with asymptomatic or stable CNS metastases were eligible. Patients with symptomatic/unstable CNS metastases were permitted if stable for ≥2 weeks after completion of definitive therapy and corticosteroids.5
ARR, absolute risk reduction; CNS, central nervous system; HR, hazard ratio; PFS, progression-free survival
Tumour assessments were performed at baseline, every 6 weeks for 18 months, and then every 12 weeks until disease progression.5 Baseline brain imaging was mandated only in patients with known or suspected CNS metastases, with follow-up imaging with confirmed CNS metastases.5
Adapted from Soria JC et al. N Engl J Med 2018.3
*Investigator’s choice of comparator.
EGFRm, epidermal growth factor receptor mutant; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor
Navigate the safety profile: FLAURA trial
Take a closer look at how TAGRISSO is administered: FLAURA trial
Learn more about how TAGRISSO works
ARR, absolute risk reduction; CI, confidence interval; CNS, central nervous system; DCR, disease control rate; DFS, disease-free survival; DoR, duration of response; EGFR, epidermal growth factor receptor; EGFRm, epidermal growth factor receptor mutant; HR, hazard ratio; L858R, exon 21 substitution; MOA, mode of action; mOS, median overall survival; mPFS, median progression-free survival; NC, not calculated; NR, not reached; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; RRR, relative risk reduction; TKI, tyrosine kinase inhibitor
GB-63982 | DOP: July 2025
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
